Lamivudine/Zidovudine Viatris

Lamivudine/Zidovudine, the active ingredient in Lamivudine/Zidovudine, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV-1 infection in adults, adolescents and children.

GNH USA supplies Lamivudine/Zidovudine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine/Zidovudine is used as part of antiretroviral therapy to suppress HIV-1 replication. - HIV-1 infection in adults: lowers plasma viral load and helps restore immune function. - HIV-1 infection in adolescents: provides virologic control as part of combination regimens. - HIV-1 infection in children: contributes to viral suppression and growth of immune parameters.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: generalized tiredness. - Anemia: reduction in hemoglobin levels. - Diarrhea: loose stools. - Neutropenia: lowered neutrophil count.

Serious or Rare Side Effects: - Severe anemia: marked drop in red blood cells requiring medical attention. - Lactic acidosis: buildup of lactate causing metabolic disturbance. - Hepatic steatosis: fatty liver disease. - Pancreatitis: inflammation of the pancreas. - Hypersensitivity reactions: rash, fever, or organ involvement. - Bone marrow suppression: pancytopenia requiring monitoring.

Before initiating therapy, clinicians should assess baseline health and monitor during treatment. - Monitor blood counts: check hemoglobin and neutrophils regularly. - Assess liver function: evaluate transaminases and bilirubin before and during use. - Review renal function: adjust dosing if significant impairment is present. - Avoid concurrent use with known mitochondrial toxic agents: limit risk of lactic acidosis. - Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Lamivudine/Zidovudine may interact with several antiretroviral and non‑antiretroviral agents.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis when combined. - Stavudine: additive mitochondrial toxicity leading to lactic acidosis. - Alcohol: potentiates hepatic toxicity and anemia.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may raise zidovudine plasma levels. - Other NRTIs: monitor for cumulative bone‑marrow suppression. - Nephrotoxic drugs (e.g., aminoglycosides): watch renal function and dosing.